Impression Healthcare launches Knight Guard
Distributor of dental health products, Impression Healthcare (ASX:IHL) has further expanded its product portfolio with the addition of night guards (The Knight Guard) to its product offerings.
IHL’s lead product Gameday mouthguards which have applications in the contact sport arena have been particularly well received, and with this new product also having the characteristics of a fitted mouthguard, the company’s entry into this new market should benefit from the expertise gained especially on the logistics side of the business.
Branded The Knight Guard, this product is aimed at addressing the problem of teeth grinding, which according to the Sleep Health Foundation affects 50% of the population on an occasional basis with 5% experiencing regular jaw clenching or Bruxism.
In keeping with the Gameday mouthguard products, IHL uses its patented self-impression system and technology to deliver high-quality teeth grinding protection direct to consumers. Importantly, this new product is included on the register of the Therapeutic Goods Administration (TGA).
IHL to benefit from experience in direct to consumer marketing and distribution
The direct to consumer model delivers considerable savings compared with the cost of purchasing similar products from dentists. The Knight Guard will be released in four product types ranging from approximately $130 to $230.
While management has a comprehensive marketing campaign planned for this new product, it has been buoyed by the level of early sales.
Looking across IHL’s product portfolio the company has made impressive progress in a short period of time, having achieved total combined sales of more than 5000 units across its Gameday, Instant Teeth Whitening (ITW) and The Knight Guard products.
Of course this is still an early stage play and investors should seek professional financial advice if considering this stock for their portfolio.
IHL’s Chief Executive, Matt Weston underlined the importance of Knight Guard and its contribution to the company’s product diversification strategy. However he also commented that IHL was focused on executing an aggressive growth strategy through acquisition and international expansion with a number of prospects currently in progress.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.